Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 February 2004Website:
http://www.oncternal.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 17:01:08 GMTDividend
Analysts recommendations
Institutional Ownership
ONCT Latest News
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the fifth dose cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the fifth cohort are receiving ONCT-534, the company's dual-action androgen receptor inhibitor (DAARI), at a dose of 600 mg taken orally once each day. The decision to proceed to this higher dose level was made by the study's Safety Review Committee (SRC) after reviewing data from the fourth dose level of 300 mg ONCT-534 daily. An initial update on ONCT-534 safety and efficacy based on prostate-specific antigen (PSA) levels from this study is expected in the third quarter of 2024 and will include data from this 600 mg dose cohort.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q4 2023 Results Conference Call March 7, 2024 5:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Hartaj Singh - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator Greetings, and welcome to Oncternal's Fourth Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $3.11 per share versus the Zacks Consensus Estimate of a loss of $3.09. This compares to loss of $4 per share a year ago.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Richard Vincent - CFO James Breitmeyer - President and CEO Salim Yazji - Chief Medical Officer Conference Call Participants Carl Byrnes - Northland Securities Hartaj Singh - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions].
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q2 2023 Earnings Conference Call August 10, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Carl Byrnes - Northland Capital Markets Hartaj Singh - Oppenheimer & Company Rosemary Li - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets Operator Greetings and welcome to the Oncternal Second Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
Oncternal Therapeutics, Inc. (NASDAQ:ONCT ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Hartaj Singh - Oppenheimer Carl Byrnes - Northland Capital Markets Rosemary Li - Cantor Fitzgerald Kemp Dolliver - Brookline Capital Markets Operator Greetings, and welcome to the Oncternal Therapeutics First Quarter 2023 Financial Results Call. [Operator Instructions] As a reminder, this conference will be recorded.
Oncternal Therapeutics (ONCT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.20 per share a year ago.
Oncternal Therapeutics (NASDAQ: ONCT ) stock is falling hard on Tuesday after the company decided to end two clinical trials. Oncternal Therapeutics has announced that it's closing its Zilovertamab Phase 3 Study ZILO-301 and its Phase 1/2 Study CIRM-0001 study.
What type of business is Oncternal Therapeutics?
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
What sector is Oncternal Therapeutics in?
Oncternal Therapeutics is in the Healthcare sector
What industry is Oncternal Therapeutics in?
Oncternal Therapeutics is in the Biotechnology industry
What country is Oncternal Therapeutics from?
Oncternal Therapeutics is headquartered in United States
When did Oncternal Therapeutics go public?
Oncternal Therapeutics initial public offering (IPO) was on 03 February 2004
What is Oncternal Therapeutics website?
https://www.oncternal.com
Is Oncternal Therapeutics in the S&P 500?
No, Oncternal Therapeutics is not included in the S&P 500 index
Is Oncternal Therapeutics in the NASDAQ 100?
No, Oncternal Therapeutics is not included in the NASDAQ 100 index
Is Oncternal Therapeutics in the Dow Jones?
No, Oncternal Therapeutics is not included in the Dow Jones index
When does Oncternal Therapeutics report earnings?
The next expected earnings date for Oncternal Therapeutics is 09 August 2024